Inclusion Criteria:

          -  Participant is Japanese

          -  Histologically or cytologically confirmed diagnosis of any locally advanced or
             metastatic solid tumors not amenable to local or other curative therapy.

          -  Participants with nonevaluable lesions are allowed.

          -  Life expectancy > 3 months.

          -  Eastern Cooperative Oncology Group performance status 0 to 1.

          -  Female participants agree to use medically acceptable contraceptive measures, should
             not be breastfeeding, and must have a negative pregnancy test before the start of
             study drug administration.

          -  Female participants of childbearing potential must understand and accept that
             pregnancy must be avoided during participation in the study.

          -  Male participants should avoid unprotected sex with women of childbearing potential
             and refrain from donating sperm during participation the study.

        Exclusion Criteria:

          -  Receipt of anticancer therapy or participation in another interventional clinical
             study within 14 days before the first administration of study drug with the following
             exceptions: Immunotherapy or biological therapy (eg, monoclonal antibodies) within 21
             days the first administration of study drug; 6 weeks for mitomycin-C or nitrosoureas;
             7 days for tyrosine kinase inhibitors.

          -  Radiotherapy within 14 days of first dose of study treatment with the following
             exceptions: 28 days for pelvic radiotherapy; 6 months for thoracic region radiotherapy
             that is > 30 Gy.

          -  Toxicity of prior therapy and/or complications from surgical intervention that has not
             recovered to ≤ Grade 1 or baseline within 7 days before starting study drug treatment
             (with the exception of anemia not requiring transfusion support and any grade of
             alopecia). Note: Endocrinopathy, if well-managed, is not exclusionary and should be
             discussed with sponsor medical monitor.

          -  Receipt of prior systemic treatment with an arginase inhibitor

          -  Immune-related toxicity during prior checkpoint inhibitor therapy for which permanent
             discontinuation of therapy is recommended (per product label or consensus guidelines),
             OR any immune-related toxicity requiring intensive or prolonged immunosuppression to
             manage (with the exception of endocrinopathy that is well controlled on replacement
             hormones).

          -  Active autoimmune disease requiring systemic immunosuppression in excess of
             physiologic maintenance doses of corticosteroids (> 10 mg of prednisone or
             equivalent).

          -  Known active central nervous system metastases and/or carcinomatous meningitis.

          -  Known active hepatitis A virus, hepatitis B virus, or hepatitis C virus infection.

          -  Known HIV infection.

          -  Active infections requiring systemic therapy.

          -  Known hypersensitivity to another monoclonal antibody that cannot be controlled with
             standard measures and/or known hypersensitivity ≥ Grade 3, or severe reaction, to
             study treatments or any of their excipients or additives.

          -  Participants with impaired cardiac function or clinically significant cardiac disease.

          -  Evidence of interstitial lung disease or active, noninfectious pneumonitis or a
             history of interstitial lung disease.

          -  Participant is pregnant or breastfeeding.